Investigation of PJ vs. Sugar on Glucose Levels in Healthy and Prediabetic Subjects (PSW)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04591782 |
|
Recruitment Status :
Active, not recruiting
First Posted : October 19, 2020
Last Update Posted : April 15, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Diabete Type 2 Pre Diabetes | Other: PomJuice Other: Water Other: Sugar Water | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 42 participants |
| Allocation: | Randomized |
| Intervention Model: | Crossover Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Other |
| Official Title: | Exploratory Study to Determine the Bioavailability of Sugar From Pomegranate Juice (PJ) vs. Sucrose |
| Actual Study Start Date : | February 1, 2019 |
| Estimated Primary Completion Date : | December 20, 2021 |
| Estimated Study Completion Date : | December 20, 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: PomJuice (PJ)
8 oz of PJ
|
Other: PomJuice
Drink 8 oz pomegranate juice |
|
Active Comparator: Sugar Water
8 oz of water with 18.6 g of glucose + 18.3 g of fructose dissolved into it
|
Other: Sugar Water
Drink 8 oz of water with 18.6 g of glucose + 18.3 g of fructose dissolved in |
|
Water
8 oz of water
|
Other: Water
Drink 8 oz water |
- Number of participants with acute response to sugar water vs. pom juice vs. water [ Time Frame: 2 hours ]Compare the difference in blood glucose response to consuming PomJ compared to the same amount of sugar (fructose and glucose) mixed in water in a cross over study design
- Number of participants with hormonal changes in response to sugar water vs. pom juice vs. water [ Time Frame: 15 days ]Compare the plasma concentration of principle hormones involved in glucose regulation (insulin, C-peptide, glucagon) , gut hormones (GLP-1 and GIP) and triglycerides.
- Number of participants with acute response of plasma nitric oxide (NO) from sugar water vs. pom juice vs. water [ Time Frame: 2 hours ]Compare the acute response of plasma nitric oxide (NO) in participants who consume sugar alone, water alone or pomegranate juice
- Impact of gut microbiome in glycemic response to pom juice vs. sugar water [ Time Frame: 15 days ]Compare the glycemic response and the ability to form microbiote urolithin from pomegranate ellagatanins in participants who consume pom juice vs. water.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 20 Years to 50 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Age 20-50 years and any racial/ethnic group
- Typically consume low fiber/polyphenol diet (beige diet)
- Healthy, normal weight individuals with a BMI of >18 to 26.9 kg/ m2 with fasting serum glucose <100mg/dL or A1c <5.7
- Prediabetic, obese individuals with a BMI of >27 kg/ m2 and fasting serum glucose >100, but <126 mg/dL or A1c >5.7% but < 6.4%]
- Subjects must read and sign the informed consent prior to participation
- Subjects must be in generally good health
- Subjects must be able and willing to comply with the requirements of the protocol.
Exclusion Criteria:
- Eating a high fiber/polyphenol diet or taking any medication or dietary supplements that interfere with the absorption of polyphenols.
- History of gastrointestinal surgery, diabetes mellitus on medications, or other serious medical condition, such as chronic hepatic or renal disease, bleeding disorder, congestive heart disease, chronic diarrhea disorders, myocardial infarction, coronary artery bypass graft, angioplasty within 6 months prior to screening, current diagnosis of uncontrolled hypertension (defined as systolic BP >160mmHg, diastolic BP > 95mmHg), active or chronic gastrointestinal disorders, bulimia, anorexia, laxative abuse, or endocrine diseases (except thyroid disease requiring medication) as indicated by medical history
- Any subject currently taking blood thinning medications such as Warfarin or Coumadin
- Currently uses tobacco products.
- Currently has an alcohol intake > 20 g ⁄ day;
- Currently has a coffee intake > 3 cups ⁄ day;
- Screening laboratory value outside of the laboratory normal range that is considered clinically significant for study participation by the investigator.
- Using prebiotics, probiotics, yogurt, and/or any fiber supplements regularly
- Allergy or sensitivity to pomegranate. Subjects will be excluded if there is a prior history of such sensitivity. Since these foods are commonly eaten and allergies are rare, subjects should be aware of this sensitivity prior to entering the study. In addition, any subject with a history of allergy or anaphylaxis of any kind will be excluded
- Taking antibiotics or laxatives within the past 3 months
- Is unable or unwilling to comply with the study protocol.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04591782
| United States, California | |
| UCLA Center for Human Nutrition, 1000 Veteran Ave. | |
| Los Angeles, California, United States, 90095 | |
| Principal Investigator: | Zhaoping Li, MD, PhD | UCLA Professor of Medicine |
| Responsible Party: | Zhaoping Li, Chief / Professor of Medicine, University of California, Los Angeles |
| ClinicalTrials.gov Identifier: | NCT04591782 |
| Other Study ID Numbers: |
18-001720 |
| First Posted: | October 19, 2020 Key Record Dates |
| Last Update Posted: | April 15, 2021 |
| Last Verified: | April 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
pomegranate antioxidants prediabetes |
|
Prediabetic State Diabetes Mellitus, Type 2 Diabetes Mellitus |
Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |

